IAC
11.6.2024 16:01:35 CEST | Business Wire | Press release
Returning to showcase the World’s Fastest Autonomous Racecar, the Indy Autonomous Challenge (IAC), presented by Bridgestone, will take on the hillclimb at the Goodwood Festival of Speed presented by Mastercard from July 11th to July 14th, 2024. This year, the IAC’s AV-24 fully autonomous racecar will be piloted by software from the PoliMOVE-MSU team, with support from the UNIMORE Racing team.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611138772/en/
The world's fastest autonomous racecar with an AI pilot coded by students from PoliMOVE-MSU team races on Goodwood Hill. Credit Indy Autonomous Challenge. (Photo: Business Wire)
The IAC has developed the AV-24, a fully autonomous racecar utilizing a Dallara chassis used in the Indy NXT series, and outfitted with a state-of-the-art robotics platform developed with leading autonomous hardware and software providers. To date, the IAC has organized autonomous racing competitions gathering 10 teams comprised of 18 universities at prestigious venues such as the Indianapolis Motor Speedway, Las Vegas Motor Speedway, Texas Motor Speedway, and Monza F1 Circuit—affectionately known as the Temple of Speed. The 2024 Festival of Speed marks the Indy Autonomous Challenge’s competitive debut in the UK, promising to test the technology in new and challenging ways.
Since its inception in 2021, the Indy Autonomous Challenge and its university teams have set several world records for high-speed ground-based autonomy:
- Autonomous land speed record of 192.2 mph
- Highest on-track speed of 180 mph
- Fastest head-to-head overtake on-track at 177 mph
- Most miles of autonomous racing accumulated: 9,000 miles.
Last year the Indy Autonomous Challenge was introduced to Goodwood in 2023 as part of Future Lab presented by Randox, illustrating the IAC’s significant role in advancing automotive driving technology through global events. Additionally, the Technical University of Munich used their autonomous racecar to conduct a low-speed scan of the Goodwood hill, crafting a digital twin of the course that will help enable this year’s fully autonomous hillclimb.
Paul Mitchell, Chairman and President of the Indy Autonomous Challenge, expressed enthusiasm about the upcoming event, stating, “We are eager to undertake the unique challenges presented by the Goodwood Hillclimb. Unlike the familiar ovals and F1 road courses, Goodwood’s Hillclimb will challenge the precision of sensor perception, GPS localization, vehicle dynamics, and path planning in new ways, providing a historical backdrop to showcase the future of high-speed autonomous mobility and the innovative university teams behind it.”
The event, part of Goodwood’s FOS TECH program, will highlight the latest in automotive technology and alternative fuels, integrating the Future Lab and STEM programs targeted at young people eager to participate in future robotics. IAC university teams’ capabilities will be showcased as they attempt an autonomous world record on the Goodwood hill. Autonomous racing will not only entertain but also offer insights and learnings towards the future of mobility, demonstrating how AI drivers will revolutionize vehicle safety and efficiency on public roads and within supply chains.
The Duke of Richmond, founder of the Festival of Speed, commented on the festival’s role in showcasing technological innovation: “This year, our new FOS TECH ethos will bring together our future technology and mobility content. Whether exploring Future Lab presented by Randox, Electric Avenue, or enjoying content on the Hill, visitors to the Festival of Speed can experience the work of groundbreaking innovators and their vision for tomorrow’s world.”
Sara Correa, Chief Marketing Officer for Bridgestone in the Americas, Europe, Middle East and Africa (EMEA) added, “What really matters is working together to collaboratively develop and advance the future of mobility. Bridgestone is proud to partner with the IAC and its young engineers to test and improve autonomous technologies through opportunities like the Goodwood Hillclimb. Motorsports are the ultimate challenge, and the learnings we gather here can be applied to the sustainable solutions we develop for society and our customers.”
Participating teams: PoliMOVE-MSU - Comprised of members from Politecnico di Milano (Italy), Michigan State University (Michigan), with the support of UNIMORE Racing - University of Modena and Reggio Emilia (Italy)
The IAC’s appearance at Goodwood Festival of Speed will be the first time that an exhibitor has graduated from Future Lab to the Hillclimb. This year’s event will also feature engaging educational sessions, where attendees can explore future technologies such as autonomous vehicles, drones, robots, augmented and virtual reality, generative AI, sensor fusion, and the Internet of Things. These topics will be the focus of a Q&A session in collaboration with Durham University's solar-powered electric car team, which has also worked with Bridgestone to advance sustainable mobility.
Earlier in June, the IAC conducted a series of training sessions on the Goodwood Hillclimb, performing fully autonomous runs of the hill, reaching speeds greater than 177 kph (110mph). Video and photo footage of the training sessions and racecar livery renders dedicated to media use can be found here.
About the IAC: The Indy Autonomous Challenge (IAC) is a non-profit corporation based in Indianapolis, Indiana (USA) that organizes racing competitions among 10 university-affiliated teams representing 18 universities from around the world. Teams program AI drivers to pilot fully autonomous racecars and compete in a series of history-making events at iconic tracks. Based in Indiana, the IAC is working to establish a hub for performance automation in the state and is harnessing the power of innovative competitions to attract the best and the brightest minds from around the globe to further state-of-the-art technology in the safety and performance of autonomous vehicles. The IAC started as a $1 million prize competition with 31 university teams signing up to compete more than three years ago, representing top engineering and technology programs from 15 U.S. states and 11 countries. Follow the IAC @IndyAChallenge on LinkedIn, Twitter, Instagram, Facebook, and YouTube.
About Bridgestone: Bridgestone is a global leader in tires and rubber building on its expertise to provide solutions for safe and sustainable mobility. Headquartered in Tokyo, the company employs approximately 130,000 people globally and conducts business in more than 150 countries and territories worldwide. Bridgestone offers a diverse product portfolio of premium tires and advanced solutions backed by innovative technologies, improving the way people around the world move, live, work and play.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611138772/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
